Amedisys Operating Income from 2010 to 2024

AMED Stock

USD 91.16 0.08 0.09%

Amedisys' Operating Income is increasing over the years with slightly volatile fluctuation. Overall, Operating Income is expected to go to about 202.7 M this year. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Amedisys generates from its operations. View All Fundamentals

Operating Income

First Reported

1993-03-31

Previous Quarter

42.2 M

Current Value

34 M

Quarterly Volatility

60.5 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Amedisys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amedisys main balance sheet or income statement drivers, such as Depreciation And Amortization of 23.7 M, Interest Expense of 32.8 M or Selling General Administrative of 819.1 M, as well as many exotic indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 0.0023 or PTB Ratio of 2.57. Amedisys financial statements analysis is a perfect complement when working with Amedisys Valuation or Volatility modules.

This module can also supplement Amedisys' financial leverage analysis and stock options assessment as well as various Amedisys Technical models . Check out the analysis of Amedisys Correlation against competitors.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Latest Amedisys' Operating Income Growth Pattern

Below is the plot of the Operating Income of Amedisys over the last few years. Operating Income is the amount of profit realized from Amedisys operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Amedisys is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Amedisys' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amedisys' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Amedisys Operating Income Regression Statistics

	Arithmetic Mean	52,864,220
	Coefficient Of Variation	359.15
	Mean Deviation	138,726,176
	Median	78,524,000
	Standard Deviation	189,863,203
	Sample Variance	36048T
	Range	722.8M
	R-Value	0.80
	Mean Square Error	13752.2T
	R-Squared	0.65
	Significance	0.0003
	Slope	34,116,082
	Total Sum of Squares	504672.5T

Amedisys Operating Income History

	2024	202.7 M
	2023	193.1 M
	2022	180.8 M
	2021	251.9 M
	2020	219.3 M
	2019	177.5 M
	2018	155.1 M

Other Fundumenentals of Amedisys

Non Operating Income Net Other

Amedisys Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Current Deferred Revenue	Common Stock	Long Term Debt	Treasury Stock	Property Plant Equipment	Good Will	Intangible Assets	Net Tangible Assets	Total Permanent Equity	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Long Term Investments	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.9	0.95	0.6	0.95	0.99	0.95	0.9	0.76	0.53	0.94	-0.92	-0.24	0.98	0.89	-0.81	0.29	0.88	0.85	0.4	0.72	0.8	0.91	-0.64	0.81
Total Stockholder Equity	0.99		0.86	0.93	0.64	0.97	0.97	0.95	0.88	0.76	0.58	0.92	-0.9	-0.24	0.97	0.88	-0.75	0.27	0.84	0.85	0.35	0.71	0.79	0.88	-0.62	0.79
Net Debt	0.9	0.86		0.9	0.56	0.78	0.91	0.74	0.83	0.63	0.37	0.98	-0.88	-0.17	0.92	0.91	-0.87	0.34	0.9	0.76	0.5	0.76	0.62	0.94	-0.56	0.65
Retained Earnings	0.95	0.93	0.9		0.47	0.87	0.94	0.85	0.87	0.81	0.29	0.94	-0.95	-0.37	0.98	0.88	-0.92	0.49	0.94	0.81	0.63	0.78	0.81	0.95	-0.66	0.84
Accounts Payable	0.6	0.64	0.56	0.47		0.66	0.58	0.56	0.43	0.13	0.78	0.52	-0.59	-0.05	0.57	0.72	-0.33	0.07	0.26	0.69	0.06	0.31	0.08	0.51	-0.6	0.17
Net Receivables	0.95	0.97	0.78	0.87	0.66		0.93	0.98	0.84	0.7	0.61	0.84	-0.88	-0.3	0.92	0.84	-0.68	0.34	0.76	0.86	0.34	0.66	0.76	0.8	-0.64	0.76
Total Liab	0.99	0.97	0.91	0.94	0.58	0.93		0.93	0.9	0.73	0.49	0.95	-0.91	-0.23	0.98	0.89	-0.84	0.31	0.89	0.84	0.44	0.69	0.79	0.92	-0.67	0.81
Total Current Assets	0.95	0.95	0.74	0.85	0.56	0.98	0.93		0.85	0.73	0.57	0.82	-0.83	-0.3	0.9	0.78	-0.66	0.29	0.76	0.82	0.3	0.63	0.82	0.78	-0.58	0.81
Short Term Debt	0.9	0.88	0.83	0.87	0.43	0.84	0.9	0.85		0.74	0.33	0.85	-0.75	-0.06	0.87	0.77	-0.72	0.32	0.84	0.65	0.36	0.61	0.8	0.83	-0.49	0.81
Current Deferred Revenue	0.76	0.76	0.63	0.81	0.13	0.7	0.73	0.73	0.74		0.16	0.71	-0.68	-0.4	0.76	0.56	-0.66	0.27	0.81	0.59	0.37	0.75	0.9	0.74	-0.22	0.85
Common Stock	0.53	0.58	0.37	0.29	0.78	0.61	0.49	0.57	0.33	0.16		0.39	-0.42	0.12	0.42	0.57	-0.08	-0.25	0.14	0.67	-0.26	0.34	0.17	0.36	-0.36	0.28
Long Term Debt	0.94	0.92	0.98	0.94	0.52	0.84	0.95	0.82	0.85	0.71	0.39		-0.89	-0.23	0.96	0.91	-0.88	0.33	0.95	0.79	0.47	0.79	0.74	0.96	-0.54	0.74
Treasury Stock	-0.92	-0.9	-0.88	-0.95	-0.59	-0.88	-0.91	-0.83	-0.75	-0.68	-0.42	-0.89		0.42	-0.96	-0.89	0.89	-0.52	-0.85	-0.9	-0.68	-0.76	-0.68	-0.91	0.78	-0.74
Property Plant Equipment	-0.24	-0.24	-0.17	-0.37	-0.05	-0.3	-0.23	-0.3	-0.06	-0.4	0.12	-0.23	0.42		-0.34	-0.19	0.45	-0.54	-0.35	-0.41	-0.61	-0.25	-0.37	-0.3	0.36	-0.37
Good Will	0.98	0.97	0.92	0.98	0.57	0.92	0.98	0.9	0.87	0.76	0.42	0.96	-0.96	-0.34		0.91	-0.89	0.4	0.92	0.86	0.54	0.75	0.79	0.95	-0.68	0.81
Intangible Assets	0.89	0.88	0.91	0.88	0.72	0.84	0.89	0.78	0.77	0.56	0.57	0.91	-0.89	-0.19	0.91		-0.82	0.34	0.81	0.9	0.43	0.79	0.58	0.94	-0.63	0.68
Net Tangible Assets	-0.81	-0.75	-0.87	-0.92	-0.33	-0.68	-0.84	-0.66	-0.72	-0.66	-0.08	-0.88	0.89	0.45	-0.89	-0.82		-0.57	-0.93	-0.73	-0.78	-0.71	-0.69	-0.93	0.66	-0.73
Total Permanent Equity	0.29	0.27	0.34	0.49	0.07	0.34	0.31	0.29	0.32	0.27	-0.25	0.33	-0.52	-0.54	0.4	0.34	-0.57		0.44	0.37	0.81	0.33	0.32	0.41	-0.5	0.33
Long Term Debt Total	0.88	0.84	0.9	0.94	0.26	0.76	0.89	0.76	0.84	0.81	0.14	0.95	-0.85	-0.35	0.92	0.81	-0.93	0.44		0.71	0.59	0.79	0.85	0.94	-0.47	0.85
Capital Surpluse	0.85	0.85	0.76	0.81	0.69	0.86	0.84	0.82	0.65	0.59	0.67	0.79	-0.9	-0.41	0.86	0.9	-0.73	0.37	0.71		0.46	0.75	0.62	0.85	-0.71	0.73
Deferred Long Term Liab	0.4	0.35	0.5	0.63	0.06	0.34	0.44	0.3	0.36	0.37	-0.26	0.47	-0.68	-0.61	0.54	0.43	-0.78	0.81	0.59	0.46		0.44	0.37	0.55	-0.66	0.45
Long Term Investments	0.72	0.71	0.76	0.78	0.31	0.66	0.69	0.63	0.61	0.75	0.34	0.79	-0.76	-0.25	0.75	0.79	-0.71	0.33	0.79	0.75	0.44		0.66	0.82	-0.25	0.71
Short Long Term Debt	0.8	0.79	0.62	0.81	0.08	0.76	0.79	0.82	0.8	0.9	0.17	0.74	-0.68	-0.37	0.79	0.58	-0.69	0.32	0.85	0.62	0.37	0.66		0.74	-0.32	0.95
Net Invested Capital	0.91	0.88	0.94	0.95	0.51	0.8	0.92	0.78	0.83	0.74	0.36	0.96	-0.91	-0.3	0.95	0.94	-0.93	0.41	0.94	0.85	0.55	0.82	0.74		-0.58	0.79
Net Working Capital	-0.64	-0.62	-0.56	-0.66	-0.6	-0.64	-0.67	-0.58	-0.49	-0.22	-0.36	-0.54	0.78	0.36	-0.68	-0.63	0.66	-0.5	-0.47	-0.71	-0.66	-0.25	-0.32	-0.58		-0.45
Capital Stock	0.81	0.79	0.65	0.84	0.17	0.76	0.81	0.81	0.81	0.85	0.28	0.74	-0.74	-0.37	0.81	0.68	-0.73	0.33	0.85	0.73	0.45	0.71	0.95	0.79	-0.45

Click cells to compare fundamentals

About Amedisys Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Amedisys income statement, its balance sheet, and the statement of cash flows. Amedisys investors use historical funamental indicators, such as Amedisys's Operating Income, to determine how well the company is positioned to perform in the future. Although Amedisys investors may use each financial statement separately, they are all related. The changes in Amedisys's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Amedisys's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Amedisys Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Amedisys. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	193.1 M	202.7 M
Non Operating Income Net Other	2 M	1.9 M

Pair Trading with Amedisys

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amedisys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amedisys will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amedisys Stock

0.76	DH	Definitive Healthcare Financial Report 2nd of May 2024	Pair Corr
0.84	GH	Guardant Health Financial Report 14th of May 2024	Pair Corr
0.76	FIGS	Figs Inc Financial Report 2nd of May 2024	Pair Corr

Moving against Amedisys Stock

0.81	GCTK	GlucoTrack	Pair Corr
0.74	WGS	GeneDx Holdings Corp Earnings Call This Week	Pair Corr
0.52	RCM	R1 RCM Inc Financial Report 2nd of May 2024	Pair Corr
0.47	HQY	HealthEquity Financial Report 3rd of June 2024	Pair Corr

The ability to find closely correlated positions to Amedisys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amedisys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amedisys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amedisys to buy it.

The correlation of Amedisys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amedisys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amedisys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Amedisys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:

How To Invest In Amedisys

Details

Is Amedisys Stock a good investment?

Details

What is Amedisys' Net Worth?

Details

Largest Health Care Providers & Services Companies

View

Largest Health Care Equipment & Services Companies

View

Check out the analysis of Amedisys Correlation against competitors.

For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Note that the Amedisys information on this page should be used as a complementary analysis to other Amedisys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for Amedisys Stock analysis

When running Amedisys' price analysis, check to measure Amedisys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amedisys is operating at the current time. Most of Amedisys' value examination focuses on studying past and present price action to predict the probability of Amedisys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amedisys' price. Additionally, you may evaluate how the addition of Amedisys to your portfolios can decrease your overall portfolio volatility.

	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Money Managers Screen money managers from public funds and ETFs managed around the world
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

Is Amedisys' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.40)

Earnings Share

(0.30)

Revenue Per Share

68.603

Quarterly Revenue Growth

0.016

Return On Assets

0.0598

The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Amedisys Operating Income from 2010 to 2024

Latest Amedisys' Operating Income Growth Pattern

Amedisys Operating Income Regression Statistics

Amedisys Operating Income History

Other Fundumenentals of Amedisys

Amedisys Operating Income component correlations

About Amedisys Financial Statements

Pair Trading with Amedisys

Moving together with Amedisys Stock

Moving against Amedisys Stock

Complementary Tools for Amedisys Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY